NASDAQ:TVTX Travere Therapeutics - TVTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $22.40 +0.97 (+4.53%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$21.47▼$22.5650-Day Range$18.47▼$21.8852-Week Range$17.97▼$30.35Volume1.16 million shsAverage Volume1.09 million shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$32.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Travere Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside43.8% Upside$32.22 Price TargetShort InterestHealthy11.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.35Based on 23 Articles This WeekInsider TradingSelling Shares$414,536 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.38) to ($3.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector789th out of 1,055 stocksPharmaceutical Preparations Industry394th out of 518 stocks 3.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.22, Travere Therapeutics has a forecasted upside of 43.8% from its current price of $22.40.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.72% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 10.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.0 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Travere Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for TVTX on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $414,536.00 in company stock.Percentage Held by InsidersOnly 4.71% of the stock of Travere Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($4.38) to ($3.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Travere Therapeutics (NASDAQ:TVTX) StockTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Stock News HeadlinesJanuary 30, 2023 | msn.comThe Latest Analyst Ratings for Travere TherapeuticsJanuary 28, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 1,550 SharesJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 27, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline Sells 852 SharesJanuary 27, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 905 SharesJanuary 27, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 2,062 Shares of StockJanuary 27, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube Sells 6,442 SharesJanuary 26, 2023 | seekingalpha.comTravere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is CriticalJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 25, 2023 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) to Post FY2022 Earnings of ($4.43) Per Share, Wedbush ForecastsJanuary 9, 2023 | finance.yahoo.comTravere Therapeutics Provides Corporate Update and 2023 OutlookJanuary 3, 2023 | finance.yahoo.comTravere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNovember 15, 2022 | finance.yahoo.comTravere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney DiseaseOctober 27, 2022 | seekingalpha.comTravere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call TranscriptOctober 27, 2022 | msn.comRecap: Travere Therapeutics Q3 EarningsOctober 27, 2022 | finance.yahoo.comTravere Therapeutics Reports Third Quarter 2022 Financial ResultsOctober 26, 2022 | msn.comEarnings Outlook For Travere TherapeuticsOctober 26, 2022 | finance.yahoo.comTravere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022October 20, 2022 | finance.yahoo.comTravere Therapeutics to Report Third Quarter 2022 Financial ResultsOctober 20, 2022 | finance.yahoo.comTravere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 17, 2022 | nasdaq.comHere's Why Travere (TVTX) is Poised for a Turnaround After Losing 22.2% in 4 WeeksOctober 14, 2022 | finance.yahoo.comAnalyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFAOctober 14, 2022 | msn.comFDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney DiseaseOctober 14, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Travere TherapeuticsOctober 14, 2022 | markets.businessinsider.comExpert Ratings for Travere TherapeuticsOctober 14, 2022 | uk.investing.comAfter-Hours Movers: Imara Gains on Merger, Travere Therapeutics Falls on PDUFA...October 13, 2022 | za.investing.comAfter-Hours Movers: Imara Gains on Merger, Travere Therapeutics Falls on PDUFA DelaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Company Calendar Last Earnings10/28/2021Today1/31/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees310Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.22 High Stock Price Forecast$42.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+44.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,090,000.00 Net Margins-123.82% Pretax Margin-123.70% Return on Equity-137.68% Return on Assets-33.98% Debt Debt-to-Equity Ratio3.73 Current Ratio4.08 Quick Ratio4.03 Sales & Book Value Annual Sales$227.49 million Price / Sales6.32 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book4.54Miscellaneous Outstanding Shares64,170,000Free Float61,151,000Market Cap$1.44 billion OptionableOptionable Beta0.48 Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)Pres, CEO & Director Comp: $1.27MMs. Elizabeth E. Reed (Age 52)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $696.68kDr. William E. Rote Ph.D. (Age 60)Sr. VP of R&D Comp: $752.35kMr. Christopher Cline C.F.A. (Age 39)CFA, Chief Financial Officer Ms. Sandra Calvin (Age 58)VP, Corp. Controller & Principal Accounting Officer Ms. Charlotte SmithSr. VP of Public AffairsMr. Casey LoganSr. VP of Corp. & Bus. Devel.Ms. Angela GiannantonioSr. VP of HRMr. Peter Heerma (Age 52)Chief Commercial Officer Dr. Jula Inrig M.D. (Age 48)Chief Medical Officer More ExecutivesKey CompetitorsBridgeBio PharmaNASDAQ:BBIOVerve TherapeuticsNASDAQ:VERVMannKindNASDAQ:MNKDZentalis PharmaceuticalsNASDAQ:ZNTLBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 1,629 shares on 1/27/2023Ownership: 0.119%Eric M DubeSold 6,442 sharesTotal: $138,503.00 ($21.50/share)National Bank of Canada FIBought 67,000 shares on 1/24/2023Ownership: 0.181%Oak Ridge Investments LLCSold 3,091 shares on 1/24/2023Ownership: 0.131%Peter HeermaSold 1,550 sharesTotal: $33,945.00 ($21.90/share)View All Insider TransactionsView All Institutional Transactions TVTX Stock - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price forecast for 2023? 7 analysts have issued 12-month price targets for Travere Therapeutics' shares. Their TVTX share price forecasts range from $17.00 to $42.00. On average, they anticipate the company's share price to reach $32.22 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2023? Travere Therapeutics' stock was trading at $21.03 at the beginning of the year. Since then, TVTX shares have increased by 4.2% and is now trading at $21.91. View the best growth stocks for 2023 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its earnings results on Thursday, October, 28th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.13. The company earned $68.20 million during the quarter, compared to analyst estimates of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 137.68% and a negative net margin of 123.82%. The company's revenue was up 33.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) EPS. What guidance has Travere Therapeutics issued on next quarter's earnings? Travere Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $212.00 million-$212.00 million, compared to the consensus revenue estimate of $212.08 million. What is Travere Therapeutics' stock symbol? Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX." Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.35%), National Bank of Canada FI (0.18%), Oak Ridge Investments LLC (0.13%), Rice Hall James & Associates LLC (0.12%), Hennion & Walsh Asset Management Inc. (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Travere Therapeutics' stock price today? One share of TVTX stock can currently be purchased for approximately $21.91. How much money does Travere Therapeutics make? Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $1.41 billion and generates $227.49 million in revenue each year. The company earns $-180,090,000.00 in net income (profit) each year or ($4.18) on an earnings per share basis. How many employees does Travere Therapeutics have? The company employs 310 workers across the globe. How can I contact Travere Therapeutics? Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280. This page (NASDAQ:TVTX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.